Lung cancer remains the leading cause of cancer death in the United States, accounting for an estimated 29% of cancer deaths in 2009.1 Pneumonectomy or lobectomy with hilar and mediastinal lymph node sampling is the gold standard treatment and offers the best option for cure of stage 1/2 nonsmall cell lung cancer (NSCLC).2 Unfortunately, only 15% of patients present with stage 1/2 disease, and many of these patients do not meet the pulmonary physiologic guidelines for lobar resection.3 In addition to lung cancer, pulmonary metastases are present in 25% to 30% of patients dying from all types of cancer.4 For some patients with oligometastatic pulmonary disease, metastectomy is associated with an improvement in survival.5 External beam radiation traditionally has been offered as the alternative to surgical resection for NSCLC or pulmonary metastatic disease. Unfortunately, the 5-year survival following radiation for stage 1 and 2 NSCLC remains low at 15% to 20%, with local recurrence being the most common mode of failure.6,7 Thermal ablation offers an intriguing therapeutic option to increase local tumor control and survival in patients with early stage NSCLC or with limited metastatic disease from nonlung primaries who are not surgical candidates because of poor cardiopulmonary reserve, anatomic constraints limiting resection, failure of traditional therapies, or refusal of operative approaches.
Thermal ablation has been shown to be effective in treating tumors in bone, kidney, and liver.8–11 Most preclinical and clinical trials have focused on demonstrating the feasibility of three modalities for pulmonary thermal ablation, namely radiofrequency (RF) ablation, microwave (MW) ablation, and cryoablation. This article discusses the unique challenges of performing thermal ablation in lung tissue and reviews the current literature regarding RF, MW, and cryoablation in the lung.